Comparison 2. Ustekinumab versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure to induce clinical remission (6 weeks)	4	1947	Risk Ratio (M‐H, Random, 95% CI)	0.91 [0.86, 0.95]
1.1 1.0 mg/kg IV	1	175	Risk Ratio (M‐H, Random, 95% CI)	0.92 [0.82, 1.04]
1.2 3.0 mg/kg IV	1	176	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.83, 1.08]
1.3 4.5 mg/kg IV	1	53	Risk Ratio (M‐H, Random, 95% CI)	0.87 [0.67, 1.11]
1.4 6.0 mg/kg IV	3	1543	Risk Ratio (M‐H, Random, 95% CI)	0.90 [0.82, 0.98]
2 Failure to induce clinical remission (6 weeks; sensitivity analysis)	3	1320	Risk Ratio (M‐H, Fixed, 95% CI)	0.92 [0.88, 0.96]
2.1 1.0 mg/kg IV	1	175	Risk Ratio (M‐H, Fixed, 95% CI)	0.92 [0.82, 1.04]
2.2 3.0 mg/kg IV	1	176	Risk Ratio (M‐H, Fixed, 95% CI)	0.95 [0.83, 1.08]
2.3 4.5 mg/kg IV	1	53	Risk Ratio (M‐H, Fixed, 95% CI)	0.87 [0.67, 1.11]
2.4 6.0 mg/kg IV	2	916	Risk Ratio (M‐H, Fixed, 95% CI)	0.92 [0.87, 0.97]
3 Failure to induce clinical response (>= 70 points; 6 weeks)	4	1947	Risk Ratio (M‐H, Random, 95% CI)	0.73 [0.66, 0.81]
3.1 1 mg/kg IV	1	175	Risk Ratio (M‐H, Random, 95% CI)	0.78 [0.61, 0.98]
3.2 3 mg/kg IV	1	176	Risk Ratio (M‐H, Random, 95% CI)	0.81 [0.63, 1.03]
3.3 4.5 mg/kg IV	1	53	Risk Ratio (M‐H, Random, 95% CI)	0.59 [0.37, 0.94]
3.4 6 mg/kg IV	3	1543	Risk Ratio (M‐H, Random, 95% CI)	0.72 [0.61, 0.85]
4 Failure to induce clinical response (>= 70 points; 6 weeks; sensitivity analysis)	3	1320	Risk Ratio (M‐H, Fixed, 95% CI)	0.78 [0.71, 0.85]
4.1 1 mg/kg IV	1	175	Risk Ratio (M‐H, Fixed, 95% CI)	0.78 [0.61, 0.98]
4.2 3 mg/kg IV	1	176	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.63, 1.03]
4.3 4.5 mg/kg IV	1	53	Risk Ratio (M‐H, Fixed, 95% CI)	0.59 [0.37, 0.94]
4.4 6 mg/kg IV	2	916	Risk Ratio (M‐H, Fixed, 95% CI)	0.78 [0.71, 0.87]
5 Failure to Induce clinical response (>=100 points; 6 weeks)	4	1947	Risk Ratio (M‐H, Random, 95% CI)	0.77 [0.69, 0.87]
5.1 1.0 mg/kg IV	1	175	Risk Ratio (M‐H, Random, 95% CI)	0.82 [0.67, 1.01]
5.2 3.0 mg/kg IV	1	176	Risk Ratio (M‐H, Random, 95% CI)	0.85 [0.70, 1.04]
5.3 4.5 mg/kg IV	1	53	Risk Ratio (M‐H, Random, 95% CI)	0.59 [0.39, 0.89]
5.4 6.0 mg/kg IV	3	1543	Risk Ratio (M‐H, Random, 95% CI)	0.76 [0.63, 0.91]
6 Failure to Induce clinical response (>=100 points; 6 weeks; sensitivity analysis)	3	1320	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.77, 0.88]
6.1 1.0 mg/kg IV	1	175	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.67, 1.01]
6.2 3.0 mg/kg IV	1	176	Risk Ratio (M‐H, Fixed, 95% CI)	0.85 [0.70, 1.04]
6.3 4.5 mg/kg IV	1	53	Risk Ratio (M‐H, Fixed, 95% CI)	0.59 [0.39, 0.89]
6.4 6.0 mg/kg IV	2	916	Risk Ratio (M‐H, Fixed, 95% CI)	0.83 [0.77, 0.91]
7 Failure to induce clinical remission ‐ 90 mg, s.c. (6 weeks)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
8 Failure to induce clinical response 90 mg s.c. (>= 70 points; 6 weeks)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
9 Failure to induce clinical response 90 mg s.c. (>=100 points; 6 weeks)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
10 Adverse events	4	2023	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.90, 1.04]
11 Serious adverse events	4	2023	Risk Ratio (M‐H, Fixed, 95% CI)	0.83 [0.58, 1.20]
12 Withdrawals because of adverse events	2	657	Risk Ratio (M‐H, Fixed, 95% CI)	0.44 [0.18, 1.05]